LXRX — Lexicon Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $662.98m
- $523.81m
- $49.80m
Lexicon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Analysis: Europe's AI bulls pin hopes on 'Jevons Paradox' after DeepSeek rout
U.S. STOCKS ON THE MOVE-Walmart, Fiserv, Rumble
U.S. STOCKS ON THE MOVE-Nordstrom, Optical Cable, Lexicon
U.S. STOCKS ON THE MOVE-Eli Lilly, Playa Hotels, Rumble
Lexicon Pharma falls after FDA declines to approve its add-on diabetes drug
Brief: Lexicon Announces Receipt Of Complete Response Letter For Zynquista (Sotagliflozin)
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
Brief: Lexicon Announces Completion Of Enrollment In Phase 2B Progress Study Of LX9211 In Diabetic Peripheral Neuropathic Pain
U.S. RESEARCH ROUNDUP-Domino's Pizza, Elastic NV, Snowflake
U.S. STOCKS ON THE MOVE-CC Holding, CBRE, Lexicon Pharmaceuticals
Lexicon Pharmaceuticals rises on plan to lay off 60% of employees
Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback (updated)
Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development
Brief: Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA
Lexicon Pharmaceuticals Inc reports results for the quarter - Earnings Summary
Lexicon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Lexicon To Present Preclinical In Vivo Efficacy Data Demonstrating Ability Of New Investigational Compound To Enhance And Maintain Semaglutide-Promoted Weight Loss